Bringing the Best of Pharmaceutical Sciences to a Wider Audience by Participating in the Open Access Week
Singapore, London (PRWEB) October 27, 2018 -- Omics International, the flag-bearer of the open access movement, is all set to commemorate the 10th International Open Access Week (October 22-28, 2018). Dr. Srinubabu Gedela, the Founder and CEO of Omics, has announced special recognition for manuscripts submitted during this period.
This year’s theme- “designing equitable foundations for open knowledge,” is an attempt at evaluating whether the open access movement has fulfilled its commitment of bringing inclusivity to the field of scientific research and identifying whether this movement has inadvertently brought about any inequities, and if yes, then how to contain and rectify these inequities.
Pharmaceutical science is a key branch of life science, aimed at improving the health statistics by aiding in the development of new therapeutic modalities and modification of the existing ones. Pharmaceutical research plays a singular role in developing new therapeutics and vaccines to prevent and manage diseases. Pharmaceutical progress has resulted in a dramatic decline in the mortality rates for diseases such as cancer, HIV/AIDS, and measles, thereby contributing to the prosperity of the society as a whole.
The global pharmaceutical drug market is estimated to reach USD 1.12 trillion in 2022. Currently, the North American pharmaceutical market is the largest in the world, and is worth USD 341.1 billion.
As pharmaceuticals represent such an essential component of public health, free access to pharmaceutical research is very important. When pharmaceutical companies are requesting for a governmental certification stating that their products are suitable for public consumption, the public requires these companies to openly disclose their research, even if doing so would end up undermining the profits of these pharmaceutical companies. Without access to such research, the public won't know if these pharmaceutical products are fit for use. The plus-points of open-access publishing format such as faster impact, greater public engagement, and wider collaboration, are all the need of the hour in the present pharmaceutical scenario, what with the world being riddled with emergent infections and enhanced chronic illnesses such as diabetes, cancer, and mental health disorders. This year’s theme for the Open Access Week is an attempt at highlighting the tough questions in the field as it attempts to become more transparent and more morally and socially responsible.
Omics International has a significant footprint in the field of pharmaceutical research, with 62 pharmaceutical science journals being published under its masthead; these include reputed journals like: the International Journal of Drug Development & Research, Pharmaceutica Analytica Acta, the Journal of Bioequivalence & Bioavailability, the Journal of Biomolecular Research & Therapeutics, and Pharmaceutical Regulatory Affairs: Open Access. These journals are dedicated to publishing breakthroughs in the field and making them available to the largest possible readership, free of cost.
Entering into the spirit of the Open Access Week, Omics International has planned several activities for its authors, reviewers, Editors, and readers. Publishing an article in any of the journal issues during the Open Access Week would directly signal the solidarity of the authors with the open-access movement.
All the Editors, authors and reviewers are requested to participate in the open access week and share their experiences with everyone, thereby making their own indelible contribution to the open access movement.
Abhishek Babu, PULSUS GROUP, http://www.pulsus.com, +91 4047482201, [email protected]
Share this article